» Articles » PMID: 31672070

Nurse-Delivered Brief Behavioral Treatment for Insomnia in Lung Cancer Survivors: A Pilot RCT

Overview
Journal Behav Sleep Med
Publisher Routledge
Date 2019 Nov 2
PMID 31672070
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

: Insomnia occurs in 50 to 80% of lung cancer survivors. Cognitive behavioral therapy is the standard treatment for insomnia (CBTI); however, treatment length and lack of psychologists trained in CBTI limits access. Brief Behavioral Treatment for Insomnia (BBTI), a nurse-delivered modified CBTI, is proposed. This feasibility pilot study sought to compare the BBTI intervention to attention control Healthy Eating Program (HEP) for insomnia in lung cancer survivors. : The participants comprised adults, 21 years of age or older with insomnia and stage I/II non-small cell lung cancer, more than 6 weeks from surgery and living in Western NY. : Participants (n = 40) were randomly assigned to an experimental (BBTI) or attention control condition (Healthy Eating Program). Thirty participants completed the study. : Participants were 66 years of age (± 7.6; range 53-82), 40% (n = 16) male, 87.5% (n = 35) Caucasian, 50% (n = 20) married, BMI 27.7 (± 5.8), and 12% (n = 5) never smokers. Baseline sleep diary sleep efficiency, ISI and other baseline covariates were balanced between the groups. Sleep efficiency improved ≥85% in BBTI group ( = .02), but not in HEP control group ( = 1.00). Mean ISI for BBTI and attention control were 6.40 ± 4.98 and 14.10 ± 4.48 ( = .001) respectively. In addition, BBTI group mean total FACT-L score improved by 6.66 points from baseline while HEP group score worsened ( = .049). : BBTI is a practical, evidence-based, clinically relevant intervention that improved sleep and quality of life in lung cancer survivors with insomnia. Additional research to evaluate efficacy, duration, and implementation strategies are essential.

Citing Articles

Health-related quality of life and mental health outcomes among cancer survivors in an insomnia intervention: a randomized controlled trial.

Kwon M, Zhu J, Wilding G, Larkin K, Gehrman P, Dickerson S Ann Behav Med. 2025; 59(1).

PMID: 39887070 PMC: 11783284. DOI: 10.1093/abm/kaae096.


Psychological Interventions for Insomnia in Patients with Cancer: A Scoping Review.

Gonzalez A, Jimenez-Torres G, De Moraes A, Geng Y, Pawate V, Khan R Cancers (Basel). 2024; 16(22).

PMID: 39594805 PMC: 11593114. DOI: 10.3390/cancers16223850.


Nurse-delivered brief behavioral treatment for insomnia in cancer survivors: a randomized controlled trial.

Dickerson S, Kwon M, Wilding G, Zhu J J Cancer Surviv. 2024; .

PMID: 39589721 DOI: 10.1007/s11764-024-01704-1.


Efficacy of non-pharmacological interventions on sleep quality in patients with cancer-related insomnia: a network meta-analysis.

Luo Y, He H, Cao C, Xu R, Tian X, Jiang G Front Neurol. 2024; 15:1421469.

PMID: 39372699 PMC: 11449704. DOI: 10.3389/fneur.2024.1421469.


Effects of nurse-led brief behavioral treatment for insomnia in adults: a randomized controlled trial.

Chang K, Lin C, Jan Y, Gordon C, Lee H, Shih C J Clin Sleep Med. 2024; 20(11):1763-1772.

PMID: 38935053 PMC: 11530976. DOI: 10.5664/jcsm.11256.


References
1.
Savard J, Villa J, Simard S, Ivers H, Morin C . Feasibility of a self-help treatment for insomnia comorbid with cancer. Psychooncology. 2010; 20(9):1013-9. DOI: 10.1002/pon.1818. View

2.
Vaupel P, Mayer A . Tumor Hypoxia: Causative Mechanisms, Microregional Heterogeneities, and the Role of Tissue-Based Hypoxia Markers. Adv Exp Med Biol. 2016; 923:77-86. DOI: 10.1007/978-3-319-38810-6_11. View

3.
Chen M, Yu C, Yang C . Sleep disturbances and quality of life in lung cancer patients undergoing chemotherapy. Lung Cancer. 2008; 62(3):391-400. DOI: 10.1016/j.lungcan.2008.03.016. View

4.
Degner L, Sloan J . Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manage. 1995; 10(6):423-31. DOI: 10.1016/0885-3924(95)00056-5. View

5.
Buysse D . GUEST EDITORIAL: Rational pharmacotherapy for insomnia: time for a new paradigm. Sleep Med Rev. 2003; 4(6):521-527. DOI: 10.1053/smrv.2000.0134. View